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Elastic fibers form a network that contributes to the 
elasticity and resilience of tissues such as the skin. His­
topathologic and ultrastructural abnormalities inithe 
elastic fibers have been observed in several diseases of 
the skin and other tissues. Recent cloning of several 
genes involved in elastic fiber architecture has lead to 
the approach of the study of elastic fiber genoderma­
toses through molecular analysis. However, in geno­
dermatoses, such as pseudoxanthoma elasticum, many 
of the genes encoding elastic fiber components have 
been excluded by genetic linkage analysis. In recent 
years, mutations in several of the genes encoding elas­
tic fiber proteins have been demonstrated in other dis­
eases. These include mutations in the fibrillin 1 gene in 
T he property of reversible extensibility, essential for the normal function of resilient tissues, such as the skin, lung, and aorta, is largely attributable to the l'resence of elastic fibers in the extracellular matrix (for review see [1-3]). Although elastin accounts for 
only 2-4% of the dry weight of human skin, perturbations in the 
elastic fiber network have been observed in several skin disorders. 
The mature elastic fiber consists of two morphologically distinct 
components: elastin and the microfibrils. Elastin is the major com­
ponent of the fibers, and is the polypeptide product of a single copy 
gene. The microfibrils, although the minor component, are com­
prised of several proteins, including the fibrillins and the microfi­
bril-associated glycoproteins, among others. Fibrillogenesis of the 
elastic fibers is thought to begin with the deposition of microfibrils, 
which form a scaffold onto which the elastic polypeptides align. 
This alignment is stabilized by the formation of intermolecular 
cross-links, known as desmosines, that confer insolubility to the 
fibers. The cross-linking process commences with the oxidative 
deamination of three of four lysine residues involved in the forma­
tion of a desmosine, initiated by the copper-dependent enzyme lysyl 
oxidase. Clearly, perturbation of the elastic fiber architecture can 
result from disturbances at any one of the stages in this complex, 
multi-step process. Because many of the genes involved in elastic 
fiber assembly have recently been cloned, molecular analysis of sev­
eral diseases has become possible. In this overview, we will high­
light recent progress in understanding the role of some of these 
genes in the pathogenesis of diseases involving the elastic fibers. 
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the Marfan syndrome, and genetic linkage of congeni­
tal contractural arachnodactyly to fibrillin 2, and, 
most recently, demonstration of abnormalities in the 
Menkes syndrome gene in X-linked cutis laxa. The first 
disorders to involve mutations in the elastin gene itself 
are, surprisingly, cardiovascular and neurobehavioral 
disorders, such as supravalvular aortic stenosis and 
Williams syndrome. These findings suggest that addi­
tional, as yet undiscovered, components of the elastic 
fiber network in the skin may hold the key to unravel­
ing the molecular basis of the elastin-related genoder­
matoses. Key words: elastin gene/genetic Unkage/s"pra"al­
,,"'ar aortic stenosis/Williams syndrome. J In"est Dermatol 
103:53S-57S, 1994 
THE HUMAN ELASTIN GENE 
Gene Structure The -70-kDa elastin polypeptide is encoded by 
an mRNA of -3.5 kb in size, which is transcribed from a single 
copy gene [1-3]. Cloning of the cDNAs corresponding to the 
human elastin mRNA facilitated the elucidation of the entire de­
duced amino acid sequence [4,5]. The protein is comprised of two 
predominant types of motifs: a) the cross-link domains, comprised 
of lysine residues separated by two or three amino acid residues 
(usually alanine), and b) the hydrophobic domains, enriched in gly­
cine, proline, and valine residues. Characterization of the intronj 
exon arrangement of the human elastin gene revealed that these two 
types of protein domains are encoded by separate exons [6]. The 
human elastin gene contains a total of 34 separate exons in -45 kb 
of genomic DNA, unlike the bovine and rat elastin genes, which 
both contain 36 exons [7]. The introns of the human elastin gene are 
relatively large, and are noteworthy in that they contain an unusual 
abundance of Alu repeat sequences clustered in introns toward the 3' 
end of the gene [6]. In the human genome, Alu repeat sequences 
occur about once every 4 kb of genomic DNA, however, in the 
elastin gene, these elements occur at four times that frequency. 
Although the precise function of Alu repetitive elements is 
currently unclear, they are thought to facilitate recombination 
events [8]' It is interesting to note that the loss of the two exons (34 
and 35) in this region of the human elastin gene occurred in a 
stepwise fashion during primate evolution, and suggests that this 
region is highly unstable. Furthermore, deletions mediated by re­
combination between Alu repetitive sequences have been observed 
in other human genes, the Alu-mediated recombination events have 
been shown to be involved in the generation of the underlying 
genetic lesions in several heritable diseases. 
Alternative SpUcing During the elucidation of the human elas­
tin eDNA, it became apparent that several overlapping cDNA 
clones were identical, except for short sequences that were included 
in some clones, yet excluded from others [4,5]. When these se-
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quences were compared with the intronj exon arrangement of the 
corresponding gene, it became clear that the differences were due to 
alternative splicing of whole or parts of exons during the post-tran­
scriptional processing of the human elastin mRNA. A total of six of 
the 34 exons in the human elastin gene undergo some degree of 
alternative splicing. Examination of these exons revealed several 
mechanisms operating to generate different isoforms of elastin. 
These include the constitutive deletion of an exon (exon 22), alter­
native selection of 5'-donor (exon 26) and 3'-acceptor (exon 24) 
splice sites, and cassette-like alternative splicing of exons 23, 32, and 
33, which all have been observed in cloned cDNAs for human 
elastin [4,5,9]. Together, these mechanisms can generate a vast en­
semble of elastin polypeptides with a slightly different amino acid 
sequence, presumably with different tissue-specific functions [10]. 
Regulation of Elastin Gene Expression Sequence analysis of 
the 5' flanking region of the human elastin gene identified several 
regulatory elements that potentially control the transcription of the 
gene [11]. The elastin gene has several features in common with 
housekeeping genes, including the absence of a canonical TATA 
box. However, two CAA IT sequences were found at locations that 
suggest that they may be functionally active in the regulation of 
elastin gene. In addition, the 5' flanking region is GC rich overall 
(approximately 66% of total nucleotides), with a high number of 
CpG dinucleotide sequences. Housekeeping genes are ubiquitously 
expressed by a variety of cells, but genes encoding tissue specific 
genes are increasingly found to contain some of these features as 
well. The promoter region of the elastin gene also contains a num­
ber of cis-elements that serve as potential binding sites for transcrip­
tionally active factors .. These include SP-l and AP-2 binding sites, 
glucocorticoid response elements, as well as TP A and cyclic AMP­
response elements (CRE) [11]. These sequences may explain 
previous observations that elastin gene expression can be modulated 
by glucocorticoids and other mediators of transcription. Functional 
analysis of the human elastin promoter suggested that the core pro­
moter necessary for basal expression of the gene is contained within 
the region -128 to -1, and the upstream sequences contained several 
up- and down-regulatory cis-elements [11]. The positive regulatory 
elements in core promoter activity could be explained at least in part 
by the presence of multiple SP-l and AP-2 binding sites within this 
region that may act as general enhancing elements. 
The presence of defined consensus cis-elements in the elastin 
promoter region suggests that elastin gene expression is subject to 
modulation at the transcriptional level. Recent studies have sug­
gested that tumor necrosis factor-a (TNF-a) decreases elastin 
mRNA abundance by suppressing the promoter activity [12] . In 
additional studies, transforming growth factor-p (TGF-{J) has been 
shown to ul'regulate the abundance of human elastin mRNA up to 
thirtyfold [13]. Evidence from transient transfection assays sug­
gested that this upregulation by TGF-p is post-transcriptional and, 
in fact, assay of mRNA stability suggested that TGF-p stabilizes the 
elastin mRNA resulting in elevated steady-state levels. Further­
more, insulin-like growth factor-l has also been shown to enhance 
elastin gene expression. In these studies, increases of elastin produc­
tion up to two- to fourfold were accompanied by an ap�roximate 
fourfold increase in the corresponding mRNA level [14J. Collec­
tively, these observations suggest that mediators of elastin gene 
expression may play a role in diseases characterized by altered accu­
mulation of elastic fibers in tissue. although the precise mechanisms 
are still largely unknown. In addition to cytokines and mediators 
released from inflammatory cells, dramatic modulation of elastin 
gene expression has also been demonstrated by vitamin D3• Specifi­
cally, incubation of cultured fibroblasts with vitamin D, in 10-7 M 
concentration resulted in an 80 -90% decrease in the total accumu­
lation of elastin polypeptides accompanied by a parallel decrease in 
steady-state levels of the corresponding mRNA [15]. 
Chromosomal Location and Genetic Polymorphism. Ex­
ploration of the role of the elastin gene in disorders such as the 
genodermatoses, Williams syndrome, or SVAS, was facilitated by 
the identification of polymorphisms in the gene (Table I). Using 
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human elastin eDNA clones as probes, chromosomal in situ hybrid­
ization resulted in localization of the elastin gene to the chromo­
somal locus 7ql1.2 in the human genome [16]. At the time, no 
elastin-related genetic disease had been linked to 7ql1.2. The iden­
tification of pol ymorphisms within the elastin gene would be useful 
in mapping heritable disorders affecting the elastin fibers. 
Currently, there are nine reported RFLPs in the elastin gene, 
though only one is found in many populations at a sufficiently high 
frequency to be informative in genetic linkage studies. A summary 
ofRFLPs in the elastin gene is presented in Table I. Two low-fre­
quency RFLPs have been reported in the Finnish population using 
HindIII and EcoRI [17]. Two additional RFLPs have been identified 
at the 3' end of the gene in the US Caucasian and African genomes 
using HinfI and AluI endonucleases [18]. A moderately informative 
HinfI RFLP was reported in the British population, located at the 5' 
end of the elastin gene [19]. Most recently, three very rare RFLPs 
have been reported detected by PstI, EcoRI, and BamHI restriction 
enzymes [20]. The only highly-informative RFLP in the elastin 
gene is a single base substitution in exon 20 (A -+ G) that results ina 
serine to glycine substitution [21]. Unlike the other reported 
RFLPs, which are currently only detectable by Southern blot analy­
sis, this RFLP can be detected by PCR amplification of the corre­
sponding genomic segment, followed by restriction endonuclease 
digestion of the PCR product with BfaI. The allelic frequency of 
this polymorphism is -0.42 (A allele)j-0.58 (G allele), with a 
corresponding PIC (polymorphism information content) of -0.42 
[21]. This RFLP proved useful in the exclusion of linkage of the 
elastin gene in pseudoxanthoma elasticum (PXE) and genetic link­
age of a vascular disease, SV AS, to 7 q 11.2, in the region of the 
elastin gene (see below). 
MOLECULAR PATHOLOGY OF ELASTIC FIBERS 
Recent cloning of several of the genes involved in elastic fiber 
assembly, including elastin, lysyl oxidase, fibrillin-l, and fibrillin-2, 
has led to genetic linkage or the identification of mutations in many 
of these genes in a variety of diseases such as Marfan syndrome in 
fibrillin-l, congenital contractural arachnodactyly (CCA) in fibril­
lin-2, and SV AS and Williams syndrome in the elastin gene (Table 
n). None of these disorders is a primary disease of the skin. A variety 
of inherited diseases of the skin display abnormalities in elastic fiber 
architecture, including PXE, cutis laxa, the Buschke-Ollendorff 
syndrome, and wrinkly skin syndrome, among others, yet in none 
of these conditions has the primary underlying defect been identi­
fied [22]. In fact, in the case of PXE, four of the genes contributing 
to elastic fiber architecture have been excluded. The first elastic 
fiber genodermatosis for which the molecular defect is known may 
be X-linked cutis laxa, with a defect in the Menkes disease gene for 
copper transport, known as Me-I. 
Pseudoxanthoma Elasticum (PXE): Exclusion of Candidate 
Genes P XE is a relatively rare clinical condition affecting tissues 
rich in elastic fibers. The diagnosis of PXE can be made without 
difficulty when the cardinal signs of the disease, such as characteris­
tic skin involvement. ocular findings, and cardiovascular manifesta­
tions are present [23]. Furthermore, although most cases of PXE 
appear to be inherited, the precise mode of transmi�sion through 
generations in many families is difficult to establish due to a delayed 
age of onset and variable expression of the PXE phenotype. The 
elastic fibers tend to be fragmented and pleiomorphic, and accumu­
late in the mid dermis where they become calcified. In addition, 
Bruch's membrane, an elastin-rich membrane behind the retina of 
the eye, becomes fragmented, resulting in the angioid streaks char­
acteristic of PXE. Although the elastic fibers are clearly abnormal in 
affected tissues, the underlying mutations and etiologic mechanisms 
remain largely unknown. Because the genetic defect in PXE has not 
yet been identified, and the genetics of the disorder are sometimes 
unclear or controversial, a new classification of PXE has recently 
been established on the basis of clinical features [24]. Once the 
genetics ofPXE are better defined, the classification will be revised 
on the basis of mutations and patterns of inheritance. 
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Table I. Polymorphisms in the Human Elastin Gene (ELN) 
Restriction Method of Location Population 
Enzyme Detection inELN Gene PIC· Screened Reference 
HindIII Southern blot Exon 18 NA Finnish [17] 
EcoRI Southern blot Exon 18 NA Finnish [17] 
Hinfl Southern blot Exons 30-36 0.28 Caucasian and [18] 
African 
AluI Southern blot Exons 30-36 0.56 Caucasian and [18] 
African 
Bfal PCRI digestion Exon 20 0.42 Ubiquitous [21] 
Hinfl Southern blot 5' end of gene 0.36 British [19] 
Pst! Southern blot Not known NA Caucasian [20] 
EcoRI Southern blot Not known NA Caucasian [20] 
BamHI Southern blot Not known NA Caucasian [20] 
• PIC, the polymorphism information content, reflects the frequency ofheterozygosiry of the polymorphism; NA, not analyzed. 
Despite the difficulties of assigning a precise mode of inheritance 
within families with PXE, we and others have undertaken genetic 
linkage studies using the candidate gene approach. Recent studies 
have identified informative restriction fragment length polymor­
phisms in four candidate genes for elastic fiber diseases, including 
elastin, fibrillin-1, fibrillin-2, and lysyl oxidase. In a study of 10 
families with clearly identifiable dominantly inherited PXE, ge­
netic linkage studies have excluded some or all of these genes in 
several families [25]. For example, the elastin gene was excluded in 
seven dominantly inherited PXE families by linkage analysis. In 
addition, in one family, all four candidate genes were excluded, 
indicating that the mutation lies in an as yet unidentified gene 
encoding an important component of elastic fibers in the skin. 
X-linked Cutis Laxa and Menkes Disease X-linked cutis laxa, 
also known as the occipital horn syndrome or Ehlers-Danlos syn­
drome type IX, is a connective tissue disorder characterized by hy­
perelastic and easily bruised skin, varicosities, bladder diverticuli, 
hernias, and skeletal abnormalities [26]. Previous biochemical and 
genetic observations confirmed linkage to the X-chromosome in 
families and disclosed a deficiency of the copper dependent enzyme, 
lysyl oxidase, in fibroblast cultures of skin from affected males [26]. 
Recently, however, the gene for lysyl oxidase was localized to chro­
mosome 5 [27,28], ruling out the possibility that mutations in the 
lysyl oxidase gene itself are responsible for X-linked cutis laxa. 
Several lines of evidence suggest that X-linked cutis laxa is a 
primary defect of copper transport and may be allelic to Menkes 
syndrome. For example, serum copper concentrations are decreased 
in both Menkes syndrome and X-linked cutis laxa, whereas copper 
concentrations in cultured skin fibroblasts are elevated [29]. This 
observation suggests a defect in copper efflux, whereas copper in­
flux is normal. A secondary reduction of lysyl oxidase is also ob­
served in Menkes syndrome fibroblasts, and is comparable to that 
observed in X-linked cutis laxa [29]. In addition, patients with both 
Menkes syndrome and X-linked cutis laxa often display neurologic 
deterioration, and some of the connective tissue disturbances appear 
Table n. R.ecently Cloned Genes Involved in Diseases of 
Elastic Fiber Architecture and Assembly 
Gene Chromosomal Primary 
Protein Locus Location Disorder 
Blastin ELN 7q11.2 SV AS, Williams syndrome 
Lxs>:l Oxidase LOX Sq23 -b 
pibrillin-l PBN-l 15q15-q21.3 Marfan syndrome 
Pibri1lin-2 FBN- 2 Sq23 Congenital Contractural 
Arachnodactyly (CCA) 
Mc-l' MNK Xq13 Menkes syndrome 
, Me·t. Menkes disease copper transport protein. 
I Lysyl oxidase is secondarily reduced in Menkes disease andEhlers-Danios syndrome 
type IX. 
in both conditions [29]. Recently, the gene for the Menkes protein 
(Mc-1) was cloned, and was shown to be a copper transporting 
ATPase [30 - 32] . This gene is interrupted in many patients with 
Menkes syndrome, and interestingly, Mc-1 expression is also mark­
edly reduced in skin fibroblasts from patients with X-linked cutis 
laxa [33]. Further studies of the two diseases should reveal the rela­
tionship between the biochemistry observed in each disorder, and 
explain how different types of mutations in the same gene underlie 
two distinct phenotypes. X-linked cutis laxa is one of the first elastic 
fiber related genodermatosis to be characterized at the molecular 
level, although the elastic fiber pathology probably results from a 
secondary effect in the dysfunction of the enzyme lysyl oxidase due 
to a defect in copper metabolism. 
Linkage of the Elastin Gene (ELN) to Supravalvular Aortic 
Stenosis (SVAS) Supravalvular aortic stenosis (SVAS) is an in­
herited vascular disorder consisting of localized or diffuse narrow­
ing of the ascending aorta [34]. Additional complications of SV AS 
include aortic aneurysms, myocardial infarction, and in some cases, 
sudden death. SVAS appears as an hour-glass deformity in the aorta 
but can also consist of diffuse hypoplasia of the entire ascending 
aorta. The histopathology of the hour-glass aorta is characterized by 
focally thickened and dysplastic aortic media with unorganized 
non-parallel elastic fibers [34]. The incidence of SVAS is estimated 
to be 1: 25,000 live births. The vascular abnormalities found in 
SV AS can be inherited as an isolated autosomal dominant disease in 
large families [35,36], or as part of a syndrome, Williams syndrome, 
which is a developmental disorder affecting multiple organ systems. 
It has been suggested that Williams syndrome may be a contiguous 
gene deletion syndrome that contains the locus for SV AS, however, 
familial dominantly inherited cases of SV AS suggest a single gene 
defect [35,36]. Using the candidate gene approach, linkage studies 
in SV AS were performed using polymorphic markers in the genes 
including several connective tissue proteins, growth factors, and 
calcium regulatory proteins, among others, and also within regions 
of cytogenetic abnormalities found in individuals with Williams 
syndrome. In one study, a combined maximum LCD score (Z) of 
5.9 at the elastin locus on chromosome 7qll.2 was found in two 
families with dominantly inherited SVAS [37]. In a second family, a 
LCD score of Z = 4.66 was found at the same location indicating 
that the underlying cause of SVAS lies in a gene at 7ql1.2, with no 
recombination events between the elastin gene and the SV AS locus 
[38]. In further support of the relationship between elastin and 
SVAS, a balanced translocation (t 6;7) was found in a family with 
autosomal dominant SVAS [39]. This translocation disrupts the 
elastin gene at exon 28 and cosegregates with the disease in this 
family, supporting the hypothesis that mutations in the elastin gene 
are the underlying cause of SVAS [39,40]. This is the first clear 
demonstration of genetic linkage between the elastin gene and an 
inherited disease. Interestingly, several other elastin-rich tissues, 
such as the skin and lung, appear to be spared in SVAS. and the only 
clinical involvement seems to be in the aorta and cardiovas-
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cular system [34 -36]. Perhaps the complex structure of elastidibers 
in the vascular system may be more sensitive to the consequences of 
mutations in the gene due to the mechanical stress on the elastic 
fibers in this tissue. 
Hemizygosity at the Elastin Locus in Williams Syndrome 
Williams syndrome is a developmental disorder involving the vas­
cular central nervous system and connective tissue. Clinical features 
of the disease include congenital heart disease. hypertension, pre­
mature aging of the skin, dysmorphic facial features, gregarious 
personality. mental retardation, infantile hypercalcemia, attention 
deficit disorder. and hyperactivity [41]. Patients with Williams syn­
drome have engaging personalities, extensive language skills, 10-
quatiousness. a cocktail party personality. and the degree of mental 
retardation is frequently underestimated in a Williams syndrome 
child [41]. Another common feature of Williams syndrome is 
SV AS, which can also be inherited as a separate autosomal dominant 
disease. as discussed above [42]. Until recently, the connection be­
tween Williams syndrome and SVAS was unclear, however, now 
that the elastin gene has been genetically linked to SV AS, the ques­
tion of whether Williams syndrome is a contiguous gene deletion 
syndrome involving the elastin locus has become intriguing. Using 
chromosomal fluorescent in situ hybridization (FISH) at the elastin 
locus in four familial and five sporadic cases of Williams syndrome, 
both inherited and de novo deletions of the elastin gene locus have 
been observed, indicating that a microdeletion of one elastin allele 
and perhaps surrounding genes results in Williams syndrome [20]. 
Hemizygosity of the elastin gene could potentially account for 
many of the connective tissue abnormalities seen in this syndrome, 
including hernias, premature aging of the skin, joint laxity and 
contractures, the hoarse voice, diverticuli of the bladder and colon, 
and dysmorphic facial features, such as loose connective tissue 
around the eyes, full cheeks, prominent lips, and dental malocclu­
sion. However. the neurobehavioral features of Williams syndrome 
are not as easily explained by hemizygosity at the elastin locus. It is 
still unclear why the connective tissue abnormalities of Williams 
syndrome are more profound and widespread than those observed in 
autosomal dominant SV AS. Perhaps specific elastin gene mutations 
may be responsible for some. of the different phenotypes between 
SVAS and Williams syndrome, or deleted genes surrounding the 
elastin locus may modify the. effect of elastin mutations and/or 
contribute to some of the disparate features such as the neurobehav­
ioral characteristics. The minimum size for the Williams syndrome 
microdeletion is 114 kb [20], and consequently. additional genes are 
probably deleted that may be involved in the pathogenesis. As re­
fined linkage and physical maps of chromosome 7q11.2 become 
available. identification of genes adjacent to elastin will be facili­
tated, and continued deletion analysis will determine if Williams 
syndrome is indeed a contiguous gene disorder involving the elastin 
locus. 
There are historical reports of the development of SV AS in rab­
bits [43]. and Williams syndrome in humans [44,45] as a result of 
transplacental absorption of vitamin D. Because it is now known 
that SV AS and Williams syndrome are the result ofhemizygosity at 
the elastin locus, it appears that exposure to vitamin D during gesta­
tion can also lead to the development of either SV AS or Williams 
syndrome, perhaps as a result of downregulation of elastin gene 
expression (see above). In fact, an epidemic of Williams syndrome 
was reported in England when megadoses of vitamin D were given 
to pregnant women to prevent rickets [44,45]. When this practice 
was discontinued, the occurrence and incidence of Williams syn­
drome in this population returned to normal. Williams syndrome 
and SV AS occur naturally due to microdeletions or rearrangements 
of chromosome 7q11.2 in the region of the elastin gene, without a 
history of prenatal exposure to excess vitamin D. Therefore, the 
historical observations that vitamin D exposure, either in pregnant 
females resulting in Williams syndrome or in pregnant rabbits re­
sulting in SV AS, may be explained in retrospect by the fact that 
vitamin D can dramatically downregulate elastin gene expression 
and mimic the effect of hemizygosity at the elastin locus. 
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In summary, SV AS and Williams syndrome are the first genetic 
diseases known to involve the elastin gene, yet neither one is a 
primary disorder of the skin. Clearly, the role of elastic fibers in the 
skin is different and perhaps less critical than the function of elastic 
fibers in other resilient tissues, such as the aorta. Because mutations 
in the elastin gene itself have been shown to cause cardiovascular 
and neurobehavioral diseases, perhaps defects in additional compo­
nents of elastic fibers in the skin must be the underlying causes of the 
elastic fiber genodermatoses. 
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